Interim Results of a Randomized Controlled Phase III Trial of Elective Nodal Irradiation Plus Erlotinib Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma (Nct00686114)
Shixiu Wu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jin Hu(Wuhan University of Technology), Fangyu Zhao(Anyang Tumor Hospital), Wei Hu(Harbin Medical University), L. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bing Xia(Hangzhou Cancer Hospital), J. Li(Chinese Academy of Medical Sciences & Peking Union Medical College), X. Zhang(Wenzhou Medical University), H. Liu(Army Medical University), Conghua Xie(Wuhan University), Kaijun Huang(Jiangsu Cancer Hospital), Honglei Luo(Huaian First People’s Hospital), Anping Zheng(Anyang Tumor Hospital), M. Chen(Sun Yat-sen University), X. Lian(Kaohsiung Medical University), X. Bian(Jiangsu Cancer Hospital), Zhouguang Hui(Chinese Academy of Medical Sciences & Peking Union Medical College), D. Du(Five Prime Therapeutics (United States)), Bangxian Tan(Affiliated Hospital of North Sichuan Medical College)
Cited by 1
Related Papers
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
|JAMA Oncology|2020|1.1k
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2022|267
Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis
|Cell stem cell|2020|251